이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Internet-based Cognitive Behavioral Therapy for Adolescents With Sleep Problems- a Feasibility Trial

2020년 10월 30일 업데이트: Mats Lekander, Karolinska Institutet
The primary objective of this study is to test the feasibility and efficacy of Internet-delivered Cognitive Behavioral Therapy (CBT) for adolescents (13 - 17 years) with sleep problems (ICBT-I). All participants will receive ICBT-I for six weeks. The investigators will also evaluate the effect of the intervention on comorbid psychiatric symptoms and function.

연구 개요

상세 설명

PARTICIPANT RECRUITMENT:

For recruitment, this pilot trial will be advertised at child and adolescent mental health services and primary care clinics, as well as through newspapers. The inclusion procedure will be carried out in two steps: 1) telephone interview and 2) face-to-face assessment.

Telephone interview: An initial telephone interview will be conducted with the adolescent/parent in order to broadly assess inclusion and exclusion criteria.

Face-to-face baseline diagnostic assessment: After the telephone screening, the adolescent along with his/her parents, are invited to a face-to-face assessment at the Child and Adolescent Mental Health clinic, including the diagnostic screening interview MINI-KID conducted with adolescents and parents jointly. Insomnia diagnoses will be established using DSM-IV criteria and levels of insomnia symptoms will be determined using ISI-a. If the ISI-a score is >10, the family will be invited to participate in the study, provided that the other inclusion criteria are fulfilled and no exclusion criteria prohibit participation. Following face-to-face assessment, participants will be provided with an information sheet and consent form.

DATA COLLECTION:

Baseline self-report measures: Participants included in the study after the face-to-face diagnostic assessment are asked to fill in self-report measures on the internet, provided via personal login and password. Participants will aslo be asked to fill in a sleep-wake diary and to wear an actigraph during seven consecutive days/nights.

Self-rating assessments during intervention: ISI-a is administered to adolescents every week during treatment.

Study participants are in regular contact (on a weekly basis) with experienced clinicians during the ICBT-I treatment. Clinicians that suspect any kind of adverse event during the assessment or treatment process will contact the parent via telephone as a first step of assessing the severity of the incident. Adverse events in this context are defined as an actual or potential situation that threatens the patient's well-being, e.g., suicide risk or an acute increase of symptoms. In the case of an adverse event, the clinician informs the study coordinator (LÅ) for a discussion of adequate action taking. If a continuation of the ICBT treatment is considered inappropriate with regard to the participants' best interest and well-being, the participant will be excluded from the study and parents/adolescents will be provided with proper referral information. Any adverse event will be reported in the planned publication of the pilot study.

Outcome measure reliability procedures: To ensure the reliability of the assessments conducted by study clinicians, all assessors will be trained by experienced instructors in the diagnostic screening instrument MINI-KID. All therapists that participate in the study will also be continuously trained in MINI-KID interviewing, assessment and diagnosing.

Post-treatment and follow-up measurement: Post-treatment measurement with actigraphy, sleep-wake diary and self-report measures will be conducted immediately after treatment (6 weeks after baseline). A follow-up measurement will be performed 6 months after treatment termination.

Referral of non-responders After the 6-month follow-up, all non-responders (defined as those participants who have not improved to a clinically meaningful degree according to ISI-a) will be referred to their local child-and adolescent psychiatric clinic for further treatment.

Statistical Analyses Outcomes will be described as significant changes in objective and subjective sleep and in clinician and self-rated measures of insomnia symptoms and comorbid symptoms, within-group effect sizes (Cohen's d), clinically significant improvement rates and remission rates. Analyses will involve t-tests as well as linear mixed-effects modeling. Randomness of missing data will be analyzed with logistic regression. Depending on the amount of missing data, multiple imputations will be employed to compensate for missing values.

연구 유형

중재적

등록 (실제)

27

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Stockholm, 스웨덴, 11364
        • BUP KFE

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

13년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Clinical levels of insomnia symptoms, as determined by ISI-a >10.
  • Age between 13 and 17 years
  • Ability to read and write Swedish
  • Daily access to the internet through a computer or similar device
  • Participants on psychotropic medication must have been on a stable dose for the last 6 weeks prior to baseline assessment

Exclusion Criteria:

  • Diagnosed with autism spectrum disorder, psychosis or bipolar disorder
  • Present risk of suicide
  • Ongoing substance dependence
  • Completed CBT for sleep disorders within the last 6 months (defined as at least 5 sessions of CBT
  • Ongoing use of central nervous system stimulant medication

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: ICBT-I
The ICBT-I treatment program is a web-based intervention consisting of six chapters/sessions that adolescents go through during six consecutive weeks.The program starts with psychoeducation regarding sleep disorders and the rationale for a cognitive behavioral intervention. The main focus for the treatment is behavioral interventions, mainly sleep restriction and stimulus control. The intervention also addresses problem solving, maintenance of treatment gains, relapse prevention and relaxation techniques. Caregivers will not actively participate in the treatment. During the treatment phase participants will be in contact with a therapist through standardized forms in the program.
Cognitive-behavioral therapy for insomnia

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in insomnia symptom severity
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Insomnia Severity Index- adolescent version ISI is a seven-item measure that yields a quantitative index of sleep impairment and treatment outcome. Total scores range from 0 to 28, with higher scores indicating greater perceived insomnia severity. The instrument has been adapted to teenagers, ISI-a, and validated on Swedish teenagers.
Change from before treatment to after (+6 weeks) and to 6 month after treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Change in subjective total sleep time
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with Sleep Wake Diary (SWD). The SWD is a subjective measure of participants' sleeping and waking times, from which total sleep time expressed in minutes is derived.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in subjective sleep onset latency
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with Sleep Wake Diary (SWD). The SWD is a subjective measure of participants' sleeping and waking times from which latency until falling asleep, expressed in minutes, is obtained.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in subjective wake after sleep onset
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with Sleep Wake Diary (SWD). The SWD is a subjective measure of participants' sleeping and waking times in which time awake expressed in minutes after sleep onset is obtained.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in subjective sleep efficiency
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with Sleep Wake Diary (SWD). The SWD is a subjective measure of participants' sleeping and waking times, from which sleep efficency is computed as the quota between time sleeping/time spent in bed, expressed in percentage. A higher percentage denotes longer time asleep.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in objective sleep total sleep time
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with wrist worn actigraph units. The actigraph unit will be worn during 7 consecutive days/nights at all three measurement occasion, from which total sleep time expressed in minutes is obtained.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in objective sleep onset latency
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with wrist worn actigraph units. The actigraph unit will be worn during 7 consecutive days/nights at all three measurement occasions, from which time in minutes before falling asleep is obtained.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in objective wake after sleep onset
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with wrist worn actigraph units. The actigraph unit will be worn during 7 consecutive days/nights at all three measurement occasions from which time being awake after sleep onset is obtained.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in objective sleep efficiency
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with wrist worn actigraph units. The actigraph unit will be worn during 7 consecutive days/nights at all three measurement occasions, from which sleep efficency is computed as the quota between time sleeping/time spent in bed, expressed in percentage. A higher percentage denotes longer time asleep.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in symptoms of insomnia
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with Athens Insomnia Scale (AIS), a self-administered questionnaire consisting of eight items to measure symptoms of insomnia. Total scores range from 0 to 24. Higher scores indicate that responders more severe insomnia symptoms.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in symptoms of depression
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with Center for Epidemiological Studies Depression Scale for Children (CES-DC). CES-DS is a 20-item self-report depression inventory that is widely used in research and has been validated on children and adolescents. Scores range from 0 to 60, in which higher scores suggest a greater presence of depressive symptoms.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in symptoms of depression 2
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Revised Children's Anxiety and Depression Scale Child and Parent version (RCADS-C/P). RCADS-C/P is a child and parent self-report measure of anxiety and depression related psychopathology. The 48 items of the RCADS measures five domains of anxiety: generalized anxiety, panic anxiety, separation anxiety, social anxiety and obsessive-compulsive anxiety, as well as symptoms of depression. For depression, values range from 0 to 30, with higher values denoting more depressive symptoms.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in symptoms of generalized anxiety
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with RCADS-C/P (see above). RCADS-C/P is a child and parent self-report measure of anxiety and depression related psychopathology. The 48 items of the RCADS measures five domains of anxiety: generalized anxiety, panic anxiety, separation anxiety, social anxiety and obsessive-compulsive anxiety, as well as symptoms of depression. For generalized anxiety, scores range from 0 to 18, with higher values denoting more severe symptoms of anxiety.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in difficulties in emotion regulation
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with Difficulties in Emotion Regulation Scale, short version (DERS-16), a self-rated questionnaire assessing difficulties to regulate emotion. DERS-16 can range from 16 to 80, with Higher scores reflect greater impairment.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in intensity of pain
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment

A Visual Analogue Scale (VAS) will be used to measure intensity of participants' current and past pain.

The scale consists of a line where the ends are defined as extreme limits (0 = no pain; 10 = worst possible pain) of pain experience

Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in daytime functioning
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with Functional Disability Inventory (FDI), a 15-item self-rated questionnaire to measure level of day-time functioning. Scores range from 0 (no disability) to 60 (severe disability).
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in daytime sleepiness 1
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with Pediatric Daytime Sleepiness Scale (PDSS), a self-report scale consisting of 8 items. Scores range from 0-32, with higher scores indicating more daytime sleepiness.
Change from before treatment to after (+6 weeks) and to 6 month after treatment
Change in daytime sleepiness 2
기간: Change from before treatment to after (+6 weeks) and to 6 month after treatment
Measured with the Karolinska Sleepiness Scale (KSS), a 9-point Likert scale, ranging from 1 to 9, with higher numbers denoting more sleepiness.
Change from before treatment to after (+6 weeks) and to 6 month after treatment

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

협력자

수사관

  • 연구 의자: Mats Lekander, PhD, Karolinska Institutet

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2018년 9월 1일

기본 완료 (실제)

2019년 12월 31일

연구 완료 (실제)

2020년 7월 1일

연구 등록 날짜

최초 제출

2018년 4월 5일

QC 기준을 충족하는 최초 제출

2020년 10월 30일

처음 게시됨 (실제)

2020년 11월 4일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2020년 11월 4일

QC 기준을 충족하는 마지막 업데이트 제출

2020년 10월 30일

마지막으로 확인됨

2020년 10월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

ICBT-I에 대한 임상 시험

구독하다